Searched over 200M research papers for "repatha dosing"
5 papers analyzed
These studies suggest that Repatha (evolocumab) is effective in significantly reducing LDL-C levels and treating various forms of hypercholesterolemia, especially in patients who are not adequately managed with statins.
20 papers analyzed
Repatha, also known by its generic name evolocumab, is a fully human monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This drug is primarily used to manage hyperlipidemia by significantly reducing low-density lipoprotein cholesterol (LDL-C) levels in the blood .
Repatha is administered subcutaneously and is available in two dosing regimens: 140 mg every two weeks or 420 mg once a month. These dosing options provide flexibility for patients and healthcare providers to choose a regimen that best fits the patient's lifestyle and medical needs .
Clinical trials have demonstrated that evolocumab is effective in various patient populations, including those with primary hypercholesterolemia, mixed dyslipidemia, and both heterozygous and homozygous familial hypercholesterolemia. When added to statin therapy, evolocumab can reduce LDL-C levels by approximately 50-60% from baseline . It is also effective as a monotherapy in statin-intolerant patients.
Evolocumab has shown significant efficacy in reducing LDL-C levels across multiple clinical trials. In 12-week phase III trials, evolocumab reduced LDL-C levels by 54.8% to 76.3% compared to placebo and by 36.9% to 47.2% compared to ezetimibe. These reductions were observed in patients on statin therapy, those who were statin-intolerant, and those with familial hypercholesterolemia .
The long-term efficacy and safety of evolocumab have been confirmed in studies lasting up to 76 weeks. The drug has been well-tolerated, with no significant adverse effects reported, making it a reliable option for long-term management of hyperlipidemia .
Repatha (evolocumab) offers a potent and flexible option for managing hyperlipidemia, particularly in patients who are unable to achieve LDL-C targets with statins alone or who are statin-intolerant. Its dosing regimens of 140 mg every two weeks or 420 mg once a month provide effective and convenient options for patients. The drug's ability to significantly reduce LDL-C levels and its favorable safety profile make it a valuable addition to lipid-lowering therapies .
Most relevant research papers on this topic